Inhibrx Biosciences, Inc. (INBX) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US45720N1037
Inhibrx Biosciences, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 1.30 m USD |
| Operating income | -135.03 m USD |
| EBIT | -127.86 m USD |
| Net income | -140.06 m USD |
| Diluted EPS – continuing operations | -9.04 USD |
Full history since 2016, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Inhibrx Biosciences, Inc.
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.
More stocks
- Shenzhen iN-Cube Automation Co. Ltd. (301312.SZ)
- Vetoquinol SA (VETO.PA)
- Precision Drilling Corporation(Calgary) (PD.TO)
- QUINSTREET, INC (QNST)
- Dongwon Ind (006040.KS)
- Guangdong Xianglu Tungsten Co Ltd (002842.SZ)
- H&K (MLHK.PA)
- China Bester Group Telecom Co Ltd (603220.SS)
- Italmobiliare SpA (ITM.MI)
- Dalian Dalicap Technology Co Ltd (301566.SZ)
- China Security & Fire Co Ltd Class A (600654.SS)
- i-80 Gold Corp. (IAUX)
Not investment advice. All data without warranty, price as of 05.11.2026. Details in the risk notice.